Screening rounds

R1

Jan 01 2013- Jan 01 2020

Sept 20

Alzheimer disease OR Alzheimer's disease OR AD OR Parkinson disease OR Parkinson's disease OR PD OR ALS OR Amyotrophic lateral sclerosis OR Huntington disease OR Huntington's disease

R2

Sept 26-Jan 01 2013- Jan 01 2020

MS (Multiple Sclerosis) OR MS OR Migraine OR Headache OR Epilepsy OR TBI OR Traumatic Brain Injury OR Stroke

R3

Sept 28

1. 01/01/2011-12/31/2012

Alzheimer disease OR Alzheimer's disease OR AD OR Parkinson disease OR Parkinson's disease OR PD OR ALS OR Amyotrophic lateral sclerosis OR Huntington disease OR Huntington's disease OR

MS (Multiple Sclerosis) OR MS OR Migraine OR Headache

1. 01/01/2011-12/31/2012

Epilepsy OR TBI OR Traumatic Brain Injury OR Stroke

1. 01/02/2020-01/01/2021

Alzheimer disease OR Alzheimer's disease OR AD OR Parkinson disease OR Parkinson's disease OR PD OR ALS OR Amyotrophic lateral sclerosis OR Huntington disease OR Huntington's disease OR MS (Multiple Sclerosis) OR MS OR Migraine OR Headache

<https://clinicaltrials.gov/ct2/download_studies?cond=Alzheimer+disease+OR+Alzheimer%27s+disease+OR+AD+OR+Parkinson+disease+OR+Parkinson%27s+disease+OR+PD+OR+ALS+OR+Amyotrophic+lateral+sclerosis+OR+Huntington+disease+OR+Huntington%27s+disease+OR+MS+%28Multiple+Sclerosis%29+OR+MS+OR+Migraine+OR+Headache&term=&type=Intr&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&phase=2&rsub=&strd_s=&strd_e=&prcd_s=01%2F02%2F2020&prcd_e=01%2F01%2F2021&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=>

01/02/2020-01/01/2021

Epilepsy OR TBI OR Traumatic Brain Injury OR Stroke

<https://clinicaltrials.gov/ct2/download_studies?cond=Epilepsy+OR+TBI+OR+Traumatic+Brain+Injury+OR+Stroke&term=&type=Intr&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&phase=2&rsub=&strd_s=&strd_e=&prcd_s=01%2F02%2F2020&prcd_e=01%2F01%2F2021&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=>

degen additional including the ones that were excluded from R1 that were excluded but should be included from new rules

R4

Extra (got lost)

R5

MS expanded terms just added Multiple Sclerosis

R6

Trials with Limited data

R7

P2/3 trials that needed to be reincluded, MS trials that we found pubs for later, ones with no results

Add 1s in round 7 column and ones that need pubs from MS category and p3s that pass the P3 test

Lons answers about symptoms

|  |  |  |
| --- | --- | --- |
| **Indication:** | **Symptom** | **Used as a measure of disease modification? (yes/no)** |
| **AD** | Insomnia | No |
| Apathy | No |
| Agitation | No |
| Sleepiness | No |
| **Huntington’s** | Chorea | DK - possibly |
| **Stroke** | Fatigue | No |
| Walking deficits | No |
| **MS** | Chronic Visual Loss Related to Optic Neuritis | DK posibly |
| Processing speed | DK – doubt it |
| Pain | No |
| **PD** | Sleepiness | No |
| Apathy | No |
| **TBI** | Mood disorders | No |
| Affect Recognition | No |
| Sleepiness | No |
| **Migraine** | Dizziness | Not in itself |

**Erika**

|  |  |  |
| --- | --- | --- |
| **Indication:** | **Symptom** | **Used as a measure of disease modification? (yes/no)** |
| Huntington’s | Chorea | Yes |
| Optical neuritis | No |
| Cognition | Yes |
| Stroke | Verbal fluency | Possibly |
| Epilepsy | Postictal Central Respiratory Dysfunction | No |

1. We’ve come across some phase 3 trials in MS that use weird endpoints. Would you consider any of the following “widely used measures of disease modification of MS” for phase 3 trials? (I am pretty sure the answer is ‘no’ but want to double check)
2. All make sense as primary-maybe not as primary endpoint
   1. fatigue-rarely
   2. walking-as secondary endpoint yes. It's called T25W
   3. spasticity-rarely
   4. processing speed-as tertiary endpoint
   5. chronic visual loss related to optic neuritis-Vision is part of the EDSS, so yes very often. some trials focused on vision. Then they used retinal fiber thicknes by OCT.
   6. cognitive disorders-in some as secondary or tertiary endpoint
   7. cognition-same
3. Athough all these endpoints are most often used in trials on secondary or primary progressive forms of the disease. In RRMS, primary endpoint is mostly annualised relapse rate

**Allow**

**Huntington’s-chorea and cognition**

**MS-** Chronic Visual Loss Related to Optic Neuritis

PD-motor function

General function scores

TASKS TO DO

* JK
  + Answer to spreadsheet?
    - Probs exclude stem cell one
  + Both excluded should we include-only ambigious answers from collabs
    - Stroke-verbal fluency
    - MS-optical Neuritis
* Me –last week of april first week of may all done and C2 written
  + - Severity
      * Make excel or look at treatment guidleines
      * Should be life threatening and no disease modifiying treatment
    - Look at modified background drugs adjuvant-should these count as prior evidence-with JK
      * All cannabidiol ones
      * Check the author email-send the drafts after figure it out (accidentally sent one
    - phase 2 or phase 3 check in matching doc— b/c of ss need to check avg enrollment for that p3 indication in that indication
    - p2/3s are included as long as they don’t say they didn’t continue?
    - Last matching questions
    - Individual indication-read tb and papers from
      * Stroke-verbal fluency in manual
      * Parkinsons update from textbook
      * Ms- Optic Neuritis
      * If anything moved from exclude to include check approval and positivity (ms emails symptoms)
    - SMD check
      * when data finalized see if other indications can go into SMD and pick outcome to put into it and make sure extracted that one if available even if not primary?
      * Check the extracted ones if there ends up being enough
      * Check Cis intervals % and for missing infor
        + Headache -if the bypass ones have 3 then need to check the rest

SEVERITY Checks

Severe

substantial reduction of years of life lived or severe disability

DMT-

A disease-modifying treatment is a pharmacologic or other intervention that affects the underlying neurobiology of the disease leading to cell death and has a clinical benefit that is measurable on clinical outcomes1

Conditions

Severe DMT SOC Severe

|  |  |  |  |
| --- | --- | --- | --- |
| Alzheimer's disease | Yes | ? |  |
| Parkinson disease | Yes | No2 | Yes |
| Amyotrophic lateral sclerosis, | Yes | Yes-Riluzole3 | No |
| Huntington's disease, | Yes | No4 | Yes |
| Relapsing Multiple Sclerosis, | No | Yes | No |
| Progressive Multiple Sclerosis, |  |  |  |
| Headache | No | Yes | No |
| Epilepsy, | ? | ? |  |
| TBI | ? | ? |  |
| Stroke | Yes | ? |  |

TreatmentSevere and untreated-PD, AD, HD

Not-headache, RMS